Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KB111 in Hailey-Hailey Disease
NCT07717346Phase 1Recruiting
- Sponsor
- Krystal Biotech, Inc.
- Start
- May 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KB111 in Hailey-Hailey disease (HHD), sponsored by Krystal Biotech, Inc. Primary endpoint: Safety and tolerability of KB111 at 12 weeks. Started May 2026; status: recruiting.
02
Drugs
KB111
03
Conditions
Hailey-Hailey disease (HHD)
Beyond the preview
Go deeper on NCT07717346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07717346.